Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 8/20 | 0.40 |
| ▸ | CNR2 | P34972 | 8/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19256235 | 0.84 | CNR2 (0.37) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL19256461 | 0.84 | CNR2 (0.37) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL9880938 | 0.82 | ALDH1A1 (0.41) | ESR1 | |
| SCHEMBL19256971 | 0.74 | CNR2 (0.36) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL19256974 | 0.72 | CNR1 (0.41) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL9883135 | 0.72 | TRPA1 (0.41) | — | |
| SCHEMBL15047823 | 0.71 | TP53 (0.40) | — | |
| SCHEMBL19256970 | 0.69 | CNR2 (0.38) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL21851485 | 0.68 | ESR1 (0.41) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL19257090 | 0.68 | CYP2A6 (0.42) | ESR1ESR2ARCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951059-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170233381-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233381-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | ESR1 4179/4885ESR2 2466/4885AR 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.